

OFFICIAL Leey

JUL 1 9 2004

Fax

Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A.

Legal Department - Patent Division

To: David Romeo, Ph.D., USPTO

Company: USPTO Fax: 703-872-9306 Phone: 703-305-4050 Date: July 19, 2004

From: Caren D. Geppert Fax: 317-276-5172 Phone: 317-651-4215 Total Pages: 9

Re:

Applicant Serial No. Filed

Edmonds Taylor Brian

09/763,994

February 27, 2001

For

Human Latent Transforming Growth Factor-B Binding Protein 3

Docket No. X-12239

Privileged and Confidential Communication

If there are any transmittal problems please call: (317) 651-2733.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

	CERTIFICATION OF FACSIMILE TRANSMISSION
I hereby certify that this paper is	being facsimile transmitted to the Patent and Trademark Office on the date shown below.
	KELLY L. RAMSEV
(1)	Type or print name of person signing certification
Signature	y K. Kansey July 19 2004
- Communication (Date

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Brian Taylor Edmonds Conf. No.: 6826 Serial No. : 09/763,994 Group Art Unit: Filing Date : February 27, 2001 1647 For : HUMAN LATENT TRANSFORMING Examiner: FACTOR-β BINDING PROTEIN 3 Romeo, David S. Docket No. : X-12239

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.121

Assistant Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir

In response to the Examiner's Office Action bearing an original mailing date of February 18, 2004, Applicants enclose herewith the following amendments and remarks that Applicants believe place the application in condition for allowance. Applicants authorize the office to charge the fee for a 2-month extension of time to Deposit Account No. 05-0840 in the name of Eli Lilly and Company.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.